Introduction
Medical practice is changed when clinical experiences and research findings are reported to the profession and the public. Trust in the authors is essential if this information is to be reliable. Unfortunately, cases of scientific misconduct, by falsification of data during a study, have long been recognized. More recently it has become evident that publication could be tainted by plagiarism, duplication of publications, inappropriate authorship and failure to obtain necessary approvals and consents [1] . While medical journal editors have tried to ensure that they publish only accurate information, they are facing challenges as the nature of scientific misconduct changes to have more subtle influences on submitted manuscripts [2] . Emerging concerns about ethical issues in biomedical publications suggest that the body of evidence available for decision making is flawed and could have the potential to harm patients. This review will examine the current controversies dominating medical publication ethics: selective reporting of the results from sponsored clinical trials and the need for consent for the use of personal health information.
Issues arising from sponsored clinical trials
Corporate sponsorship of clinical trials influences the relationships among industry, medical investigators and academic institutions to an unexpected extent. Conflicts of interest arise because of financial inducements to physicians and academic institutions (finders' fees or excessive administrative budgets) [3 ,4] .
Anesthesia research has focused on new drug developments since the 1950s. Early trials by single investigators involved small numbers of patients in academic centres. Randomized controlled trials (RCTs) were introduced to eliminate the influence of variability in the study population which provided evidence of drug efficacy and adverse outcomes. Large numbers of patients in multicentre trials, funded by pharmaceutical companies, became typical. The Bayh-Dole Act (1980) in the USA heralded increased collaborations between industry and academia. Government health regulatory agencies required the conduct of RCTs for drug marketing approval, the pharmaceutical industry sought to recover drug development costs quickly by early marketing of new drugs, while physicians wanted to hasten medical innovation.
In order to enrol more subjects, some physicians ignored exclusion criteria, threatened to withdraw treatment and altered patient records. Competition for access to research subjects became intense, allowing commercial groups, Contract Research Organizations, to flourish. These operate in the community, independent of academic institutions. They may attract university faculty, or employ community-based physicians who are not qualified researchers. Consequently, the sponsor has more control over study design, subject selection, data collection and analysis of the results [3 ,4] . The disruption to pre-existing relationships between academia and industry has far reaching implications.
Selective reporting of data
Physicians involved in sponsored trials introduce bias when they have conflicts of interest. Literature reviews have revealed that financial conflicts of interest are pervasive and can distort the reporting of clinical trial results. Gross et al. [5] analysed 268 RCTs published in the Annals of Internal Medicine, British Medical Journal, Journal of the American Medical Association, Lancet and the New England Journal of Medicine between 1 April 1999 and 31 March 2000. In 100 sponsored studies, authors disclosed their relationships with the sponsor as employment (30%), consultant (22%), grant recipient (18%), stock owner (7%), speaker (7%) and advisory board (5%). Bekelman et al. [6] examined studies published between January 1980 and October 2002 that disclosed financial links among authors, academic institutions and sponsors of the study. A quarter of the authors had received industry funding and some institutions held equity in companies that supported their research programmes.
The impact of these relationships on publication of results was considerable. Sponsored trials often used a placebo control to increase the likelihood of drug efficacy and consistently generated pro-industry findings. There was convincing evidence of publication delays while filing for drug patents, and of the withholding of data from the investigators by the sponsor. To address this situation, Ferris and Naylor [7 ] propose standardization of clinical trial budgets to control levels of reimbursement for physicians in a clinical trial. However, Yusuf [8 ] opposes any increased regulation of research and seeks a review of current guidelines and more government research funding.
The possibility that clinical care decisions may be made without complete and frank disclosure of study data is disturbing. In the UK, a policy decision against government funding for a new, expensive drug to treat multiple sclerosis was problematic. Patient advocacy groups lobbied for government funding approval, while the pharmaceutical company pressured to the same end. The government advisory body, the National Institute for Clinical Excellence, reversed the decision following a cost-benefit analysis that was made without full disclosure of all data held by the pharmaceutical company [9 ] .
Selective reporting of data occurs in both sponsored and government funded clinical trials. Melander et al. [10] examined 42 placebo-controlled studies of five selective serotonin reuptake inhibitors submitted to the Swedish drug regulatory authority for marketing approval, with 38 publications arising (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) . They identified duplicate publication associated with pooled data and selective reporting of results that biased the conclusions in favour of the test drug. Similarly, Chan et al. [11 ] compared 48 protocols for randomized trials funded by the Canadian Institutes of Health Research (1990-1998) with 68 related journal publications. In 40% of trials the primary outcomes differed between protocols and publications. Efficacy and harmful outcomes were incompletely reported and biased towards reporting statistically significant efficacy results. It is not surprising that selective reporting was identified in both sponsored and government funded studies, because budgets for the latter often have to be supplemented from other sources.
Some of these problems raised by sponsored clinical trials are emerging in the ongoing case of the withdrawal of US Food and Drug Administration (FDA) approval for marketing an effective arthritis drug [12] . Approval of the drug, in 1999, was based on data that did not appear in the peer-reviewed literature until 18 months later. Early concerns about the drug's cardiovascular safety profile were discounted in the direct-to-consumer advertising by the pharmaceutical company (sales exceeded $1 billion annually) and the FDA did not require further studies. A serendipitous finding in a placebo-controlled trial of the drug in patients with colon cancer, who were free of cardiovascular disease, revealed an increased risk (from 1.9 to 3.5%) of myocardial infarction or stroke in patients taking the drug. Recognition of a major public health risk, during the 5 years that the drug was prescribed, has led to questions about deficiencies in the government drug-approval process as well as the sponsored trials.
Governance of clinical research
Good practice guidelines in the conduct of research are difficult to enforce and violations are easy to find. The online Warning Letter Index of the FDA shows that 52 warning letters were sent to institutional review boards in the US between 1997 and 2004. Inspections had identified non-compliance with regulations; failures to have written protocols for the review process, document activities or provide ongoing review of studies [13] . A random audit of 58 clinical trials between 2002 and 2004 found 36 violations of regulations that resulted in warning letters to clinical investigators. Most resulted from deviations from the research protocol or flaws in the consent process, but 8% described study misconduct, including data fabrication [14 ] .
Governance and monitoring of research may be regulated or unregulated by governments, with weak enforcement practices and considerable reliance on ethics review committees to manage conflicts of interest, safeguard the validity of scientific protocols and ensure protection of human subjects. Data Safety Monitoring Boards offer some extra protection in monitoring trials and undertaking interim data analyses. They can enforce early stopping rules because of unexpected adverse events or early proof of efficacy [15] . Weaknesses of the ethics review system may lead to more government regulation of ethical review committees to harmonize the review process [16] . Whereas ethics review committees are charged with overseeing research, their approval of a study does not remove ethical and legal obligations from researchers, funding agencies, sponsors or academic institutions for the conduct of the study and the protection of human subjects. Adherence to ethical guidelines is increasingly dependent on local policy development, professional conduct and legal rulings.
Compliance with journal policies
About 500 medical journals base their editorial policies on 'The Uniform Requirements for Manuscripts Submitted to Biomedical Journals' formulated by the International Committee of Medical Journal Editors (ICMJE). In November 2001 an ICMJE amendment required a guarantee that investigators in multicentre trials had access to all data, that the manuscript was controlled by the authors and that they were involved in the study design [17] . Individual journals gave detailed instructions to authors [18] and systematic journal peer-reviewed processes were in place [19 ] .
Clinical Study Agreements (CSAs) affect the validity of research conduct and reporting of results [20 ]. Schulman et al. [21] analysed the contractual agreements with sponsors in multicentre trials. This revealed poor compliance rates with the ICMJE guidelines at 108 academic institutions in the USA. Only 1% of CSAs required monitoring by a Data Safety Monitoring Board and 17% placed limits on confidentiality duration (median of 5 years). Investigators could access on site data, but only 1% had unimpeded access to all data from multicentre trials. Analysing data from one site in a multicentre trial is scientifically invalid and introduces bias into the report. These restrictive contracts limit a site investigator's independence in subsequent publication of the trial results.
Attempts to harmonize standards in CSAs and protect publication rights were more successful in Toronto, Canada [22] . The university and eight affiliated hospitals agreed to a CSA format that preserved academic independence and integrity in accordance with the ICMJE guidelines. This specified that investigators would be able to submit a manuscript within 6-12 months of completion, allowing a reasonable period for the sponsor to review the contents, but preventing unreasonable delay in reporting the results. In the first 9 months of implementation, 152 CSAs complied closely. None allowed censorship or suppression of data (100%). Publication delays were only possible in 11 agreements that had been negotiated before standardization (7%). Compliance for premature disclosure of results for safety concerns was weaker (82%) but was corrected in later agreements. These early Toronto experiences provide a model for other academic centres to follow as they accommodate the evolving interests of academic institutions, researchers and industry.
Registration of clinical trials
An important initiative by government funding agencies, in several countries, requires registration in a public database of all RCTs before they commence [23 ,24 ] . Trials will receive an International Standard Randomised Controlled Trial Number that has to be cited in all related publications. The ICJME guidelines were updated in September 2004 to include this change. They now state that 'they require member journals to make registration in a public registry as a condition of submission of a clinical trial report for consideration for publication' [25 ] . This move should prevent selective reporting of data. Sponsors will not be able to conceal data or overestimate favourable results. Although editors still have to accept assurances from authors about the ethical conduct of the work, they know that the trial results will have public scrutiny. Clinical decision-making will once again be made on a reliable body of evidence in medical publications.
Issues in obtaining informed consent
There are legal and ethical obligations on a researcher to obtain a subject's informed consent for research [26] . The subject is entitled to have all necessary information needed to make an autonomous, voluntary decision to participate in a clinical trial. Ethics review committees want a signed consent form, and the sponsor's contract requires consent. The investigator may have a contractual obligation with a sponsor that prevents disclosure of some information, while the physician's relationship with a patient may require sharing some confidential information. So, the consent process has potential for conflicts of interest. The investigator's responsibilities are breached if valid consent is not obtained. If the subject is harmed, then legal action may follow.
Documentation of consent in clinical trials
In 1964, two New York physicians published the results of a cancer trial in which they injected cancer cells into chronically ill patients. They claimed to have oral consent, but did not use the word cancer. A court case ensued, with a ruling that withholding this information invalidated the consent [27 ] . Now, 40 years later, expectations are higher. Confirmation of both informed consent from research subjects and ethics committee approval of the study are mandatory before a manuscript can be accepted for publication in a medical journal [17] . Nevertheless, there are reports that journals demonstrate low rates of compliance with their own policies. In 1999, reports of child health research published in five major journals contained no statement that ethics approval or consent had been obtained in 60% of studies [28] . Five major medical journals did not disclose consent in 26% of articles, or ethics approval in 31%, before 1997. They improved in the next 18 months, with omissions in only 18% of articles [29] . Review of 1189 studies in six leading anaesthesia journals in 2001 documented that ethics committee approval had been obtained in 71% and informed consent in 66%; this is very close to the rates in general medical journals. Prospective trials usually included both, but only 2-3% of case reports indicated either protection [30] .
Consent process issues
Ethics review committees may give conditional approval to a study, subject to modifications to the consent form, usually seeking clarification of risks and benefits to participants [31 ] . Patients have trouble separating clinical and research procedures and more than half agree to participate, and sign a consent form, without understanding the risks involved [32 ] . Using sham protocols, Treschan et al. [33] obtained a 41% participation rate, including 9% who did not understand the high risks and painful procedures involved. If monetary inducements are offered, patients will ignore a degree of risk to participate [34 ] . At the same time, participants are wary of financial payments to investigators and 90% want these to be disclosed [35 ] . Research in children requires their assent as well as parental permission. Tait et al. [36] found that children of 7-12 years old only partially understood the study issues. While 30-89% understood any issue, children over 11 years had a better understanding than younger children.
The wording of the consent form has to be in lay terms and comprehensible to the subject. In the UK, standard descriptions of scientific terms are recommended. For example, randomization is described as 'the groups are selected by a computer which has no information about the individual' [37 ] . Concerns about obtaining consent on the same day as surgery were addressed by Brull et al. [38 ] . They found that 80% of participants in minimalrisk clinical trials in the ambulatory setting understood the purpose of the trial, 67% felt under no pressure to participate and only 7% considered that they had been exposed to some risk.
The subject may not always be the person who provides their own consent. Often, parents are the surrogate decision-makers for young children. However, a recent court ruling in the Kennedy Krieger study in the USA (which had placed families in housing with various levels of lead contamination to determine toxic levels of exposure in children) stated that a parent cannot consent to a child participating in non-therapeutic research [39 ] . If challenges to this decision are unsuccessful, children could be denied the benefits of much future research. In Germany, review of non-therapeutic research in children is not standardized and is more likely to be approved if the risks are low [40 ] .
International research collaborations with developing countries have to satisfy the ethical standards of both countries. Investigators need study approval from their home country that will depend on obtaining written consent from participants. In the host country, local ethics approval should be obtained, even if this does not allow for a systematic review, to avoid the perception of exploitation of the population [41 ] . Community and local cultural influences may mean that a person defers to family or community leaders, who must agree to their participation [42 ] . The Westernized concept of informed consent is not understood in many host countries, where respect for a person's autonomy can mean respect for these traditional relationships. National guidelines for the ethical conduct of research in human subjects are beginning to address cultural issues. For example, Aboriginal and Torres Strait Islanders are a large minority in Australia that face serious health problems. In 2003, government research ethical guidelines were developed to emphasize the importance of their key values of 'spirit and integrity' as binding all other values for that group in the past, present and future [43] .
Consent for use of healthcare information in publication Privacy laws have been enacted that protect a person's right to access and control of their personal health information. They include the Health and Social Care Bill of 2001 in the UK, the Health Insurance Portability and Accountability Act of 2003 in the USA and the Personal Information Protection and Electronic Documents Act of 2004 in Canada. Some countries have existing legislation (e.g. Australia has the Privacy Act of 1988, section 95A) that provides a framework to ensure privacy protection of health information that is collected, used or disclosed in the conduct of research and the compilation or analysis of statistics relevant to public health or public safety, and in the conduct of public health service management activities.
Ethical argument supports the view that privacy is a basic human right that should be respected, and can only be breached with the consent of that individual. This changing ethical and legal climate around the use of patient information has been seen as a barrier to clinical teaching, research and publication. Contemporary practice requires ethics committee approval and explicit consent for research participation. Most definitions of research rely on the criterion of systematic inquiry or investigation. Clinical trials meet this standard and the obligation to obtain consent to use data from participants is clear. There is less consensus on when consent is needed for other uses of an individual's healthcare information. Data collection from a large number of patients for public health or epidemiological studies is essential for healthcare management decisions. Individual consent is waived, based on the social justice argument that one patient will not be identifiable, and the benefits to healthcare are greater than any risk to patients. However, patients are not in full agreement with access to health records for research without consent in the UK [44 ] . If audits and quality assurance studies are submitted for publication in a journal, then they are regarded as research and need ethical approval and patients' consent [45 ] .
A case report (or case series) is not an interventional study or qualitative research. Arguably, it could be regarded as empirical research and require ethics committee review for publication. However, it does use a patient's health information. Therefore, publication of a case report could breach professional confidentiality and compromise a physician's duty of care. Identification of a patient is made more difficult when information is anonymized, but the information is still being used without consent [46] . The ICMJE guidelines' latest revision requires informed consent for case reports and suggests that the subject should read the manuscript to be fully informed [17] . Difficult editorial decisions have led to a pragmatic interpretation of the privacy laws to require patient consent for publishing their health information unless there are exceptional circumstances [47 ,48 ] . In the absence of consent, or over a refusal, publication would be considered if the patient is untraceable, a reasonable person would not object to publication of the material or the article contains important clinical information that has public health importance.
Conclusion
Awareness of the current controversies generated by sponsored clinical trials and privacy legislation has already led to changes in ethical guidelines for medical research and biomedical publication. Government health regulatory agencies may need to review their policies and legislate that health information obtained for research can never be used for third party interests that could harm participants. We should do whatever is needed to restore and maintain the integrity of medical journalism.
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